Gavi

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

Jhpiego pledges support to countries working to eliminate cervical cancer

Retrieved on: 
Wednesday, March 6, 2024
International, Cervical cancer, Research, Global Financing Facility, SUCCESS, World Bank, PAHO, International development, World Health Organization, Gavi, Pan American Health Organization, Molina Healthcare, UNICEF, HPV, Jhpiego, Bill, WHO, Vaccine

Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .

Key Points: 
  • Baltimore, Md., March 06, 2024 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, Jhpiego joined a historic wave of commitments to ending cervical cancer as a public health problem as part of the global Cervical Cancer Elimination Initiative meeting in Cartagena de Indias, Colombia .
  • Jhpiego is also committed in supporting at least five other countries for HPV vaccine coverage improvement and/or implementation of tailored interventions to increase HPV vaccine coverage.
  • Jhpiego has long been committed to integrated programs that link improved screening and treatment for cervical cancer as well as accelerating vaccine uptake.
  • We are inspired by these new commitments to work together across the whole spectrum of cervical cancer responses; together we have the potential to save many more women’s lives.”

Alcanza and Greater Gift Partner to Honor Clinical Research Participation on Giving Tuesday

Retrieved on: 
Monday, November 13, 2023
Meal, Feeding America, Research, Gavi, Clinical trial, Culture, Vaccine, ChromeOS, Pharmaceutical industry

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Ahead of Giving Tuesday, Alcanza Clinical Research is excited to announce its affiliation with Greater Gift, a non-profit organization dedicated to promoting awareness of the importance of clinical research and fostering a culture of gratitude and recognition within the clinical research community.

Key Points: 
  • BOSTON, Nov. 13, 2023 /PRNewswire/ -- Ahead of Giving Tuesday, Alcanza Clinical Research is excited to announce its affiliation with Greater Gift, a non-profit organization dedicated to promoting awareness of the importance of clinical research and fostering a culture of gratitude and recognition within the clinical research community.
  • Throughout the year, Alcanza has provided support to Greater Gift through financial donations and leadership.
  • Jennifer Byrne, a long-time clinical trial executive, founded Greater Gift in 2010 with an idea to recognize clinical trial participants by donating in their honor.
  • Visit www.greatergift.org to explore how Greater Gift is making an impact on clinical research by celebrating the unsung heroes behind medical advancements.

Global Impact, on Behalf of the Advancing Health Online Initiative (AHO), Announces Collaboration with Gavi, the Vaccine Alliance at the Concordia Annual Summit

Retrieved on: 
Tuesday, September 19, 2023
Online, MSD, Learning, NJ, Private sector, General assembly, United Nations, Meta, Vaccination, Public, Policy, COVID-19, AHO, Global health, United Nations General Assembly, Research, Global Impact, Vaccine hesitancy, Organization, SBC, Gavi, Merck, Social, Merck & Co., Health, Immunization, Social media, Pharmaceutical industry, Marketing

AHO’s goal is to support effective integration of social media as a core component of social behavior change (SBC) to improve health outcomes.

Key Points: 
  • AHO’s goal is to support effective integration of social media as a core component of social behavior change (SBC) to improve health outcomes.
  • To achieve this, AHO collaborates with organizations working at the intersection of technology, global health, and SBC.
  • Vaccine hesitancy long precedes the lack of confidence witnessed globally during the COVID-19 pandemic and may stem from distrust in the vaccine provider and medical system.
  • VaxSocial will launch a call for proposals in several Gavi-supported countries including India, Nigeria, and Indonesia.

SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine

Retrieved on: 
Thursday, August 24, 2023
MSD, Vaccine, Partnership, Joint, SK, Life, Typhoid fever, Vaccination, Diarrhea, Hilleman Laboratories, Biotechnology, Infection, IVI, Ministry of Food and Drug Safety, International Vaccine Institute, Fever Dream, World Health Organization, MFDS, Constipation, Research, Temperature, Abdominal pain, Science, Ministry, Salmonella enterica subsp. enterica, Risk, Water, Gavi, Nausea, Memorandum of understanding, Bill, Climate, Mortality, WHO, Health, Headache, Bill & Melinda Gates Foundation, Mental health, Safety, Skin, Fatigue, Disease, Pharmaceutical industry, Food, Wellcome, Rickettsia typhi

SK bioscience and Vaxxas have officially entered into a Joint Development Agreement.

Key Points: 
  • SK bioscience and Vaxxas have officially entered into a Joint Development Agreement.
  • This collaboration is set to revolutionize vaccine delivery by developing a novel vaccine-delivery device combination product using Vaxxas' high-density microarray patch (HD-MAP) platform technology with SK bioscience's proprietary typhoid vaccine.
  • Under the agreement, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid™ that was jointly developed by SK bioscience and the International Vaccine Institute (IVI).
  • SK bioscience collaborated with Wellcome and the IVI on the development of a trivalent invasive non-typhoidal Salmonellosis vaccine candidate in 2019.

Gavi, the Vaccine Alliance, and the Eleanor Crook Foundation Announce $2 Million Investment in an Integrated Child Survival Project

Retrieved on: 
Wednesday, June 14, 2023
Vaccine, Partnership, Private, Vaccination, Malnutrition, Research, Death, US, GAVI, Sovereign, Risk, ECF, Child, Gavi, Mortality, Immunization, Conference, Caregiver, Dietary supplement

MADRID, June 14, 2023 /PRNewswire/ -- Gavi, the Vaccine Alliance, and the Eleanor Crook Foundation (ECF) announced at the Global Vaccine Impact Conference a US$2 million joint investment in the NutriVax Project, an integrated nutrition and immunization research partnership. Each organization will contribute US$1 million to this innovative project, which will integrate life-saving interventions that traditionally have been separate – delivery of immunizations and malnutrition prevention products. Research funded by this investment has the potential to be ground-breaking for continuous improvement in countries hit by the double burden of malnutrition and low vaccination coverage.

Key Points: 
  • MADRID, June 14, 2023 /PRNewswire/ -- Gavi, the Vaccine Alliance, and the Eleanor Crook Foundation (ECF) announced at the Global Vaccine Impact Conference a US$2 million joint investment in the NutriVax Project, an integrated nutrition and immunization research partnership.
  • Each organization will contribute US$1 million to this innovative project, which will integrate life-saving interventions that traditionally have been separate – delivery of immunizations and malnutrition prevention products.
  • Research funded by this investment has the potential to be ground-breaking for continuous improvement in countries hit by the double burden of malnutrition and low vaccination coverage.
  • The Eleanor Crook Foundation is excited to join forces with the Gavi Alliance to test this innovative bundle at scale."

SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum

Retrieved on: 
Tuesday, May 23, 2023
Epidemic, Coalition for Epidemic Preparedness Innovations, Pan American Health Organization, SK, Multilateralism, WEF, Glocalization, Coalition, PAHO, CEPI, World Health Assembly, COVID-19, GAVI, African Center for Economic Transformation, Messenger, RVMC, Rochester Regional Health, Gavi, WHO, Vaccine, Ahn, World Health Organization, Pharmaceutical industry, Security (finance), Immunization, Health

Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event.

Key Points: 
  • Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event.
  • The RVMC is a global initiative launched at the World Economic Forum (WEF) in May 2022 to address inequality in vaccine distribution between few rich countries and low- and middle-income countries during the COVID-19 pandemic.
  • SK bioscience came up with a regional-based vaccine hub as a business model during the COVID-19 pandemic when inequality in COVID-19 vaccine distribution was exposed.
  • Currently, SK bioscience is preparing to establish the regional vaccine hubs in the Middle East, Africa, Southeast Asia, and Latin America.

Pediatric Vaccines Global Markets Report 2022: Impacts of COVID-19, Market Revenue Data for 2020 and 2021, Estimates for 2022, and CAGR Projections through 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
COVID-19, Consumer, Health, Pharmaceutical, Children, BCG, Investment, Incidence, Pfizer–BioNTech COVID-19 vaccine, CoronaVac, China National Pharmaceutical Group, Chickenpox, Pfizer, Vaccine, WHO, Dros, GlaxoSmithKline, Abbott Laboratories, Whooping cough, Mumps, Gavi, Merck & Co., Hepatitis, Measles, AstraZeneca, Global health, Child, Diphtheria, Mortality, Bharat Biotech, Vaccine-preventable diseases, Organization, COVID-19, Tetanus, UNICEF, Pharmaceutical industry

This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.

Key Points: 
  • This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.
  • The report also covers market projections through 2027 and estimates market shares for key players, as well as pediatric vaccines by type and by application.
  • The report also discusses the impact of the COVID-19 pandemic on this market.
  • Vaccines are one of the most significant advances in global health and are the most cost-effective strategy to reduce child mortality.

PharmaJet Needle-free System Selected to Deliver Intradermal Polio Vaccine in Nigerian Campaign

Retrieved on: 
Tuesday, November 8, 2022
Health, Medical Supplies, Medical Devices, CE marking, United Nations, Review, Global Polio Eradication Initiative, U.S. FDA, LGA, World Health Organization, Injection, Sias, GPEI, Vaccine, Certification, Stockholm Environment Institute US Center, Gavi, Centers for Disease Control and Prevention, UNICEF, Public health, OPV, PQS, Polio, World, Use, Partnership, Bill & Melinda Gates Foundation, IPV, System, CDC, Rotary International, Multimedia, Research, Paralysis, WHO, CEO

View the full release here: https://www.businesswire.com/news/home/20221108005025/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221108005025/en/
    Kangethe Ngure, Regional Director for Africa, PharmaJet, demonstrating Tropis device use to trainers in Sokoto, Nigeria.
  • The Nigeria pilot campaign will combine the nOPV2 oral vaccine with an intradermal polio vaccine (1/5 of a full IPV dose) administered with the PharmaJet Tropis NFIS.
  • We are pleased to be selected for the polio vaccine campaign in Nigeria to curtail the spread of cVDPV2, said Chris Cappello, President and CEO of PharmaJet.
  • Intradermal administration of polio vaccine with the PharmaJet Tropis NFIS has already been successfully used in mass vaccination campaigns in Somalia, Pakistan, Cuba, and The Gambia.

Global Typhoid Fever Vaccines Market Report 2022: Increasing Government & NGO Initiatives to Raise Awareness Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, People, Vaccine, Ministry, Route of administration, Water, Typhoid fever, Immunity, Industry, List of health departments and ministries, WHO, CAGR, Drinking water, TCV, Time-invariant system, Region, Subclinical infection, Constipation, Headache, Croydon typhoid outbreak of 1937, Fever, Gavi, Partnership, Genetically modified bacteria, Salmonella, US, Mouth, Centers for Disease Control and Prevention, Center, Administration, Nausea, Organization, Marketing, Salmonella enterica subsp. enterica, Symptoms of COVID-19, Awareness

The "Typhoid Fever Vaccines Market, by Vaccine Type, by Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Typhoid Fever Vaccines Market, by Vaccine Type, by Route of Administration, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea.
  • Typhoid fever vaccines are the biological formulations, which provide immunity and protect an individual against typhoid fever.
  • Increasing initiatives by governments and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to drive the typhoid fever vaccines market growth during forecast period.